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ABSTRACT 
Purpose. Catheter-tissue contact is critical for effective lesion creation in radiofrequency catheter 
ablation (RFCA). In a multicenter prospective study, we assessed the relationship between catheter 
contact force (CF) during RFCA for paroxysmal atrial fibrillation (AF) and clinical recurrences 
over a mid-term follow-up.  
Methods. All patients underwent RFCA for paroxysmal AF by antral pulmonary vein (PV) 
isolation, aiming at entry and exit conduction block in all PVs. A new open-irrigated tip catheter 
with CF  sensing  (SmartTouchTM, Biosense Webster Inc. CA) was used. All patients were followed 
for at least 12 months and the relationship between CF and clinical outcomes assessed.  
Results. One year follow-up was available in 92/95 of the patients enrolled. Acute PVI was 
achieved in 100% of the veins. Mean CF during RFCA was 12.2±3.9 g. Mean Force Time Integral 
(FTI) was 733±505 gs. Following the 3-month blanking period, 17 (18%) patients experienced at 
least 1 atrial tachyarrhythmia relapse. There was no statistical difference in mean CF (13±3.4 g vs 
12±4 g, p=0.32) and mean FTI (713±487 gs vs 822±590 gs, p=0.42) between  patients with and 
without arrhythmias recurrences. Recurrences were recorded in 22% of patients achieving a mean 
FTI value below the median of 544 gs and in 15% of patients with a mean FTI value above the 
median (p=0.64).  
Conclusions. RFCA with CF data during PV isolation for paroxysmal AF improves physician’s 
knowledge on catheter-tissue contact. In the present dataset, however, higher CF values did not 
impact mid-term clinical RFCA outcome.  
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INTRODUCTION 
The creation of a durable radiofrequency (RF) lesion depends on several parameters, including 
catheter tip electrode size, temperature, orientation, RF pulse duration, power, blood flow, and 
catheter to tissue contact (1-4). The wide diffusion of open irrigated catheters (5-8) has reduced the 
role of temperature in monitoring RF lesion formation. Recently development of new contact force 
(CF) sensor catheters has alowed measurement of the tip to tissue CF during the RF ablation 
procedure. Optimization of electrode-tissue contact during RF catheter ablation for pulmonary veins 
(PV) isolation impacts on procedure parameters by significantly reducing procedure and 
fluoroscopy times, without increasing acute complications (9-11). Preliminary data suggest a 
potential benefit of real-time CF sensing technology in reducing atrial fibrillation (AF) recurrence 
during the first year after PV isolation (11,12). The aim of this multicenter prospective study was to 
assess the relationship between catheter CF during RF catheter ablation for paroxysmal AF and 
clinical recurrences during a mid-term follow-up.  
 
METHODS 
Patients’ selection. As previously described (10) this multicenter prospective study enrolled 95 
patients in 9 Italian centres (see the Appendix) for a 3-month period. Patients aged between 18 and 
90 years with  documented symptomatic AF episodes refractory to drug therapy (Class I or  III 
drugs) and  self-terminating within 7 days were included.  
This study followed the principles outlined in latest update of the Declaration of Helsinki and all 
patients signed informed consents.  
Ablation procedure and contact force measuring. Detailed ablation procedure and CF measuring 
has been previously described (10). Briefly, after transseptal catheterization,  3D electroanatomic 
maps of the left atrium and PVs  were reconstructed using a nonfluoroscopic navigation system 
(CARTO 3®, version 2, Biosense Webster Inc., Diamond Bar, California, USA) (7,13). Maps were 
acquired during AF or sinus rhythm using respiratory gating. Fast anatomic mapping or imaging 
integration with a pre-acquired computed tomography or magnetic resonance scan was used, 
according to operators’ preference. RF pulses were delivered using the 3.5-mm Thermocool 
SmartTouchTM (Biosense Webster, Inc., Diamond Bar, CA, USA) in power control mode. RF 
power was set between 30 and 35 W depending on different left atrial sites and  the catheter tip was 
irrigated by saline at a flow rate of 2 mL/min during mapping and of 30 mL/min during ablation. 
RF was delivered up to 60 seconds or until local electrogram amplitude was reduced > 80% to 
produce a circumferential lesion around the proximal part of each PV’s ostium or around ipsilateral 
PVs according to anatomy. The lesion around the PV ostium was created by sequential point-by-
point application of RF energy or by continuously dragging the catheter, according to operators’ 
preference.  A circular decapolar or duodecapolar mapping catheter (LASSO®, Biosense Webster 
Inc, Diamond Bar, CA, USA) was used to confirm PV electrical isolation with demonstration of 
entry and exit block. Resumption of left atrium to PV conduction was evaluated for 30 minutes after 
ablation. In case of reconnection, PVs were newly isolated targeting the residual electrical 
breakthroughs.  
Operators involved in this study had previous experience in the use of Thermocool SmartTouchTM 
catheter in a 6-month period prior to study commencement, and they were encouraged to navigate 
the catheter with a limited use of fluoroscopy.  
The real time visualization of the CF values, during both the mapping and ablation phase, was 
available. During RF delivery, it was recommended to make every effort to reach and maintain a 
displayed CF value between 10 and 40 g.  
For all ablation sites, CF data were recorded and exported after the procedure for off-line analysis.  
During each RF application maximum, minimum, and mean CT values, obtained by averaging 
values sampled every 50 ms, were stored and subsequently analysed. Force Time Integral (FTI) 
expressed in g*s and defined as the integral of the CF-time curve during the ablation period in 
which the catheter was located in the segment of interest was also calculated and analysed.  
Follow-up. After discharge patients were followed for 12 months, with a clinical visit and a 12-lead 
electrocardiogram scheduled at 1, 3, 6, and 12 months. In addition, a 24-hour Holter monitoring was 
obtained at 3 and 12 months. Moreover, patients were instructed to obtain an ECG in the event of 
palpitations. No antiarrhythmic medication was prescribed following ablation. 
If there was documented recurrence of symptomatic AF and the patient required antiarrhythmic 
drug therapy, a previously ineffective but tolerated class 1 or class 3 (sotalol) drug was the preferred 
option. 
Ablation was deemed successful in the absence of symptomatic or asymptomatic atrial 
tachyarrhythmias lasting more than 30 seconds identified on surface ECG or on Holter monitoring, 
off antiarrhythmic drug therapy. As early relapse of atrial tachyarrhythmias within the first 3 
months after RF ablation may be a transient phenomenon, this transition period was excluded from 
the final analysis (14). 
Statistical analysis. Normally distributed continuous variables were expressed as mean (±SD) and 
compared by unpaired Student's t test. Skewed variables were expressed as median (25-75 quartiles) 
and compared by the runk-sum test. Normality was assessed by the Shapiro-Wilk test. Categorical 
variables were presented as counts and percentages, and compared by Chi square test (Pearson, 
Yates or Fisher’s exact test as appropriate). The actuarial probability of freedom from AF after 
ablation was calculated using the  Kaplan-Meier method . Differences between the curves were 
tested for significance by the log-rank statistic. A p value <0.05 was considered statistically 
significant.  
 
RESULTS 
Procedural data. Complete one year follow-up was available in 92/95 (97%)  patients; three 
patients were lost after 6 months of follow-up.  All patients underwent successful ablation achieving 
acute PV isolation in 100% of the veins. Overall procedure time, fluoroscopy time, and ablation 
time were 138±67, 14.3±11.2  and   34±20 min, respectively. Mean CF during ablation was 
12.2±3.9 g. Mean FTI was 733±505gs. Three groin haematoma were observed. No stroke/TIA, 
pericardial effusion, or cardiac tamponade were reported within 30 days from the procedure. 
Clinical outcome. Following the 3-month blanking period, 17 (18%) patients experienced at least 1 
episode of atrial tachyarrhythmia. In Table I are summarized the clinical characteristics of the study 
population, there was no statistical difference  between patients with and without arrhythmias 
recurrences with the exception of an higher prevalence of recurrences among females. Comparing 
radiofrequency energy applications between the group of patients with and the one without 
recurrences, there was no statistical difference in mean CF (13±3.4 g vs 12±4 g, respectively;  
p=0.32) and mean FTI (713±487 gs vs 822±590 gs, respectively; p=0.42). In Table II are reported 
the percentages of CF values 5-10g, 11-20g, and 21-30g, in patients with and without AF 
recurrences percentage. There was no difference in the percentage of CF values among patients 
with and without AF recurrence when the suggested minimum value of 10 g was achieved. 
Similarly, there was no statistically significant difference in the median value of mean CF [12 (9.8-
22) g vs 11.1 (6.7-23.7) g, p=0.64] and FTI [520 (361-2065) gs vs 561 (143-2724) gs, p=0.51] 
values in patients with vs those without recurrences. Arrhythmias recurrences were recorded in 22% 
of patients achieving a mean FTI value below the median of 544 gs against 15% of patients with a 
mean FTI value above the median (p=0.64). Figure 1 shows the Kaplan–Meier survival curve of 
patients free  arrhythmia recurrences during the 12-month follow-up according to FTI quartiles. No 
statistically significant difference was observed among the four groups (p=0.43). 
 
DISCUSSION 
Main findings. In this multicenter study on the use of a new technology which allows visualization 
of CF values and CF direction, performed with operators not blinded to CF values, higher catheter-
tissue CF values, achieved during PV isolation for paroxysmal AF, did not significantly impact 
mid-term clinical outcome. 
Previous studies. Preliminary experience of RF catheter ablation in patients with AF by means of 
catheters able to assess catheter-tissue contact, by means of optical fibers, impedance measurement, 
and magnetic sensors, have shoved how higher FTI and mean CF values during ablation allow 
reduction of both  procedural and fluoroscopy  time (9-11), without increasing complications. 
Moreover, CF data allowed the identification of  key areas where CF was poor, related to higher 
probability of acute and sub-acute reconnection (15,16). Availability of real time CF information 
during PVI has been associated with a significantly lower acute and 3-month PV reconnection rate. 
In the TOCCATA study (12) 32 patients with paroxysmal AF underwent PV isolation by using a 
RF ablation catheter with a CF sensor integrated at its tip, and they were followed for 12 months. 
All patients treated with an average CF of < 10 g (5 of 5 patients) experienced recurrences, whereas 
80% of the patients treated with an average CF of > 20 g (8 of 10 patients) were free from AF 
recurrence at 12 months. The analysis of the average force-time integral showed that 75% of the 
patients treated with < 500 gs were recurrent whereas only 31% of the patients treated with > 1000 
gs had recurrences at 12 months. The authors, based on this small population, concluded that CF 
during catheter ablation for AF related to RFCA clinical outcome. Marijon et al (11) first 
demonstrated the benefit of CF technology use in reducing AF recurrence during the year following 
PVI, when compared to a non-CF catheter. Sixty patients with symptomatic paroxysmal AF were 
enrolled in this prospective trial, comparing circular antral catheter ablation using either the CF 
catheter used in the present study (CF group) or a non-CF open-irrigated catheter (control group). 
The incidence rates of AF recurrence were 10.5% (95% CI, 1.38–22.4) in the CF group, and 35.9% 
(95% CI, 12.4–59.4) in the control group (p= 0.04). After adjustment of potential confounders, the 
use of CF catheter was found to be associated with a lower AF recurrence (OR 0.18, 95% CI 0.04–
0.94, p= 0.04).   
Present study. For the first time in a multicenter experience, our data demonstrates that CF 
improves physician’s knowledge on Catheter-tissue contact reducing procedure and fluoroscopy 
times, but not significantly impact on mid-term clinical outcome. Only a trend towards a better 
outcome in patients with mean FTI values above the median value was observed. 
Many factors might explain the discrepancy of our results compared to previous published data. 1) 
Although there is a growing evidence that catheter–tissue CF is a major determinant for RF ablation 
lesion size and quality, Olson et al.(4) demonstrated equivalent ablation lesion size with RF energy 
delivered with intermittent tissue contact over a longer period of time when compared to lesions 
created with constant catheter contact. This hypothesis seems to be confirmed by the findings (9,11) 
that CF guided ablation decreased RF time as compared with ablation performed with standard 
catheters. Also in our experience (10) optimization of electrode-tissue contact during RF catheter 
ablation for PV isolation significantly reduced procedure and fluoroscopy times. In fact, increasing 
RF energy duration in case of low or unknown contact may lead to similar clinical results. 2) In our 
study operators were not blinded to the CF value and, during RF delivery, it was recommended to 
make the maximum effort to reach and maintain a displayed CF value between 10 and 40 g. In fact, 
mean CF during ablation was 12.2±3.9 g, higher than that (< 10 g) predicting poor outcome in 
previous studies (Reddy et al  (12)). 3) One of the advantages of CF technology is the possibility to 
visualize real time direction and orientation of the catheter’s tip enabling immediate recognition of 
catheter dislodgement/sliding (11). This feature is independent from CF value and unmeasurable in 
a routine clinical setting.  
Limitations. 
The number of patients enrolled in each centre was limited and this might increase the range of data 
variability, and the bias of operators’ dependent outcome. However, this observational prospective 
study is the largest to date available and provides a representative picture of the real-life scenario of 
the use of CF sensing for AF ablation. Larger cohorts are needed to confirm or exclude the trends 
observed in the present study. 
Another potential limitation of the study was the different techniques used to perform PVI. Infact 
the lesions around the PV ostium were created by sequential point-by-point application of RF 
energy or by continuously dragging the catheter, according to operators’ preference. We did not 
evaluated the interlesion distance with both approaches. Recently, Park et al (17) demonstrated that 
acutely durable PV isolation can be achieved when RF lesions are delivered with a mean CF > 10 g 
and an interlesion distance < 5 mm. 
Conclusions. RFCA with CF data during PV isolation for paroxysmal AF  improves physician’s 
knowledge on Catheter-tissue contact. In the present dataset, however, higher CF values did not 
impact mid-term clinical RFCA outcome. Further studies randomly comparing implementation or 
not of CF data on RFCA outcome are therefore needed. 
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Appendix 
Participating centers (listed in alphabetical order): 
Ospedale Sant’Anna, Ferrara (Matteo Bertini, Lina Marcantoni, Claudio Pratola); Ospedale 
Morgagni, Forlì (Alberto Bandini, Paolo Golia); Casa di Cura Montevergine, Mercogliano 
(Francesco Solimene, Giovanni Donnici); Casa di Cura Mediterranea, Napoli (Assunta Iuliano, 
Giuseppe Stabile); Policlinico Casilino, Roma (Leonardo Calò, Ermenegildo De Ruvo, Luigi 
Sciarra); Ospedale Sandro Pertini, Roma (Antonello Castro, Marialuisa Loricchio); Azienda 
Ospedaliera Santa Maria Nuova, Reggio Emilia (Nicola Bottoni, M Iori, F Quartieri); Città della 
Salute e della Scienza, Department of Medical Sciences, University of Turin (Matteo Anselmino, 
Federico Ferraris, Fiorenzo Gaita); Ospedale di Circolo e Fondazione Macchi, University of  
Insubria, Varese (Roberto De Ponti, Raffaella Marazzi, Lorenzo A Doni). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table I. Clinical characteristics of study population 
 Study Population 
(92 pts) 
Recurences 
Group (17 pts) 
No recurences 
Group (75 pts) 
P 
Mean age (years) 58±11 (range 24-82) 58±13 58±10 0.83 
Male sex 84% 65% 88% 0.02  
Left atrium diameter 
(mm) 
40±5 (range33-55) 39±7 41±5 0.39 
Left ventricle ejection 
fraction (%) 
58±8 (range 40-65) 60±2 58±9 0.34 
Body mass index > 30 5% 0% 6% 0.33 
Previous stroke/TIA 4% 0% 5% 0.33 
Heart disease 
    Hypertensive  
    Ischemic 
    Valvular 
    Dilated 
cardiomyopathy 
51% 
46% 
7% 
4% 
4% 
47% 
41% 
0% 
6% 
0% 
52% 
47% 
8% 
4% 
5% 
0.71 
0.68 
0.23 
0.73 
0.33 
Diabetes  7% 0% 8% 0.23 
 
Table II. Percentage of mean CF values in patients with and without AF recurrence. 
 A 
5g < CF ≤ 10 g 
B 
11g < CF ≤ 20g 
C 
21g < CF ≤ 30 g 
No AF recurrence (75 
pts) 
38.7 %(29) 54.7% (41) 6.6% (5) 
AF recurrence (17 pts) 6 % (1) 88% (15) 6% (1) 
Pts= patients; CF= contact force; A vs B p=0.024, B vs C p=1; A vs C p=0.31.   
 
FIGURE LEGENDS 
Figure 1. Kaplan–Meier survival curve of patients free of AF during the 12-month follow-up (3-
month blanking period), according to the FTI quartilies . 
 
 
 
